Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Provided By GlobeNewswire
Last update: Jul 23, 2025
Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio
New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence
Read more at globenewswire.com
